ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Thyroid Cancer

Thyroid Cancer

Selumetinib has received Orphan Drug Designation status by the US Food and Drug Administration to be used as an adjuvant treatment in patients with stage III or IV differentiated thyroid cancer.

A new study is calling for a change in name for certain thyroid tumors. Patients diagnosed with what is currently known as noninvasive encapsulated follicular variant of papillary thyroid carcinoma have a very low risk for recurrence and therefore, researchers have suggested renaming the condition.

Despite a large increase in the diagnosis of thyroid cancer during the last few decades, a new study indicates that thyroid cancer incidence may be leveling off.

Thyroid lesions identified in pediatric patients were often found to have one of the molecular abnormalities commonly seen in adults with thyroid lesions.

Researchers have identified several characteristics of metastatic papillary thyroid cancer shown on preoperative ultrasound—such as node matting—that are associated with extranodal extension, an important prognostic factor linked with this disease.

A retrospective cohort study showed that body mass index and body surface area are predictive of certain behaviors of papillary thyroid carcinoma.

An increased rate of adverse effects is seen in patients with differentiated thyroid cancer who are being treated with the tyrosine kinase inhibitor sorafenib.

Pages

Subscribe to Thyroid Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.